Jazz Pharmaceuticals (JAZZ) Given a $208.00 Price Target by Piper Jaffray Companies Analysts

Piper Jaffray Companies set a $208.00 price objective on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a report issued on Wednesday morning. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus raised their price objective on Jazz Pharmaceuticals from $180.00 to $205.00 and gave the stock a buy rating in a research note on Wednesday, August 8th. BMO Capital Markets raised their price objective on Jazz Pharmaceuticals from $201.00 to $206.00 and gave the stock an outperform rating in a research note on Wednesday, August 8th. Zacks Investment Research cut Jazz Pharmaceuticals from a buy rating to a hold rating in a research note on Tuesday, July 10th. Citigroup raised their price objective on Jazz Pharmaceuticals from $162.00 to $205.00 and gave the stock a buy rating in a research note on Tuesday, July 10th. Finally, BidaskClub upgraded Jazz Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, July 24th. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $190.61.

Shares of JAZZ stock traded up $1.78 during mid-day trading on Wednesday, reaching $142.19. 1,743,725 shares of the company were exchanged, compared to its average volume of 498,591. Jazz Pharmaceuticals has a fifty-two week low of $130.15 and a fifty-two week high of $184.00. The company has a current ratio of 3.76, a quick ratio of 3.62 and a debt-to-equity ratio of 0.54. The company has a market capitalization of $9.93 billion, a P/E ratio of 14.87, a PEG ratio of 0.89 and a beta of 1.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings results on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping analysts’ consensus estimates of $3.32 by $0.26. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 25.44%. The business had revenue of $469.37 million during the quarter, compared to the consensus estimate of $482.64 million. During the same quarter last year, the company earned $3.22 earnings per share. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. On average, research analysts predict that Jazz Pharmaceuticals will post 11.71 EPS for the current year.

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,300 shares of the firm’s stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $159.45, for a total value of $207,285.00. Following the sale, the chief executive officer now directly owns 278,615 shares in the company, valued at $44,425,161.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Matthew P. Young sold 700 shares of the firm’s stock in a transaction on Monday, October 15th. The shares were sold at an average price of $158.08, for a total value of $110,656.00. Following the completion of the sale, the chief financial officer now owns 32,768 shares in the company, valued at $5,179,965.44. The disclosure for this sale can be found here. Insiders sold 34,678 shares of company stock worth $5,959,173 over the last quarter. 3.90% of the stock is currently owned by company insiders.

A number of hedge funds have recently bought and sold shares of JAZZ. Stratos Wealth Partners LTD. bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $106,000. Tiverton Asset Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $198,000. Moloney Securities Asset Management LLC bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $204,000. FDx Advisors Inc. bought a new stake in Jazz Pharmaceuticals in the second quarter valued at $244,000. Finally, Cadence Capital Management LLC bought a new stake in Jazz Pharmaceuticals in the third quarter valued at $263,000. Institutional investors own 92.95% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: Treasury Bonds

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply